Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study.

Vasiliadou, Ifigenia, Breik, Omar, Baker, Holly, Leslie, Isla, Sim, Van Ren, Hegarty, Gemma, Michaelidou, Andriana, Nathan, Kannon, Hartley, Andrew, Good, James, Sanghera, Paul, Fong, Charles, Urbano, Teresa Guerrero, Lei, Mary, Petkar, Imran, Ferreira, Miguel Reis, Nutting, Chris, Wong, Kee Howe, Newbold, Kate, Harrington, Kevin, Bhide, Shree and Kong, Anthony (2021) Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. Cancers, 13 (6). ISSN 2072-6694. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

[img]
Preview
Text (PDF file format)
cancers-13-01413.pdf - Published Version
Available under License Creative Commons Attribution 4.0.

Download (10MB) | Preview
Official URL: http://www.mdpi.com/journal/cancers

Abstract

Nivolumab is an anti-PD-1 monoclonal antibody currently used as immunotherapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of disease progression after platinum-based chemotherapy. This study evaluates real-world safety and treatment outcomes of non-trial nivolumab use. A retrospective multicenter cohort study of patients with recurrent/metastatic HNSCC treated with nivolumab between January 2017 and March 2020 was performed. Overall, 123 patients were included. The median age was 64 years, the majority of patients were male (80.5%) and had a smoking history (69.9%). Primary outcomes included overall response rate (ORR) of 19.3%, median progression-free survival (PFS) of 3.9 months, 1-year PFS rate of 16.8%, a median overall survival (OS) of 6.5 months and 1-year OS rate of 28.6%. These results are comparable to the CHECKMATE-141 study. Of 27 patients who had PD-L1 status tested, positive PD-L1 status did not significantly affect PFS ( = 0.86) or OS ( = 0.84). Nivolumab was well tolerated with only 15.1% experiencing immune-related toxicities (IRT) and only 6.7% of patients stopping due to toxicity. The occurrence of IRT appeared to significantly affect PFS ( = 0.01) but not OS ( = 0.07). Nivolumab in recurrent/metastatic HNSCC is well tolerated and may be more efficacious in patients who develop IRT.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: QZ Pathology. Oncology
WN Medical imaging. Radiology
WU Dentistry. Oral surgery
Divisions: Clinical Support > Immunology
Related URLs:
Depositing User: Jamie Edgar
Date Deposited: 15 Apr 2021 09:18
Last Modified: 15 Apr 2021 09:18
URI: http://www.repository.uhblibrary.co.uk/id/eprint/4204

Actions (login required)

View Item View Item